<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1154">
  <stage>Registered</stage>
  <submitdate>7/03/2006</submitdate>
  <approvaldate>7/03/2007</approvaldate>
  <actrnumber>ACTRN12607000160437</actrnumber>
  <trial_identification>
    <studytitle>Intravesical Gemcitabine</studytitle>
    <scientifictitle>A Phase ll trial to measure the response rate (Rate of recurrence following treatment) ,toxicity and safety of weekly intravesical gemcitabine in patients with transitional cell carcinoma of the bladder.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Superficial Bladder Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravesical gemcitabine 2g weekly for 6 weeks</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the response rate of intravesical gemcitabine in patients with transitional cell carcinoma of the bladder (Rate of recurrence following treatment)</outcome>
      <timepoint>Three monthly cystoscopies +/- biopsy for one year following initial treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the toxicity and safety of weekly intravesical gemcitabine gemcitabine.</outcome>
      <timepoint>For 6 weeks during the intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the systemic exposure of gemcitabine when given by an intravesical route with weekly haematology, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) for 8 weeks and liver function tets (LFTs) and biochemistry (UECs) fortnightly during treatment.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital signs</outcome>
      <timepoint>Recorded weekly pre and post treatment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity and safety</outcome>
      <timepoint>Assessed at a clinic visit after the third and sixth treatment and laboratory tests (the weekly blood tests for 8 weeks).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic blood samples</outcome>
      <timepoint>Obtained prior to intravesical treatment , then at 30, 60, 90, 120 and 180 minutes after the start of the first instillation of gemcitabine only.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must have either i) newly diagnosed superficial transitional cell carcinoma of the bladder, up to G3cT1, previously untreated by intravesical chemotherapy (Group A), or,ii) recurrent superficial transitional cell carcinoma of the bladder after at least one previous course of intravesical Bacillus Calmette-Guerin (BCG) or Mitomycin (Group B). At least 12 weeks must have elapsed since the last BCG or Mitomycin treatment. Pathologic or cytologic confirmation of transitional cell carcinoma.  Males or females are eligible Karnofsky Performance Status (KPS) &gt;70%  Adequate marrow function defined as neutrophils &gt; 1.5x109/l and platelets &gt;100 x109/l Adequate hepatic function defined as total bilirubin &lt; 1.5 x normal and aspartate aminotransferase (AST), alanine aminotransferase (ALT) &lt; 3 times normal Informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Prior radiation to the bladder. Previous radiation to other sites in the pelvis (eg. Prostate) is allowed, provided no more than 25% of the pelvis was included in the radiation (RT) field, and all side effects from RT have resolved. Muscle invasive disease at baseline cystoscopy Untreated urinary tract infection or abscess within the previous 7 days Other concerns that in the opinion of the investigator, would make it difficult or unethical for a patient to undergo intravesical treatment within approximately 6 weeks of baseline cystoscopy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St George Hospital, Kogarah</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eli Lilly Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The treatment for recurrent bladder tumour following trans-urethral resection (TUR) continues to be problematic. This protocol is a phase ll trial of gemcitabine directly instilled into the bladder of patients with transitional cell carcinoma who have undergone a standard TUR. The objectives of the study are to determine if intravesical gemcitabine is capable of reducing the rate of tumour recurrence in the bladder. Patients with transitional cell carcinoma who are at risk of recurrence following TUR, or who have failed previous standard treatment with intravesical BCG are eligible for the study. Patients will receive weekly bladder instillation of 2000mg of gemcitabine via a catheter, followed by re-evaluation of disease at 3 months by the urologist. Toxicity is expected to be minimal. The results of this trial will allow a phase lll trial comparing intravesical gemcitabine with BCG or mitomycin C to be undertaken.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St George Public Hospita</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/02/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Public Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/06/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Private Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/06/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Port Macquarie Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>11/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/08/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Public Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Private Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/10/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Paul de Souza</name>
      <address>Cancer Centre
St George Hospital
Gray Street
Kogarah NSW 2217</address>
      <phone>+61 2 93503910</phone>
      <fax>+61 2 93503910</fax>
      <email>Paul.deSouza@SESIAHS.HEALTH.NSW.GOV.AU</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Linda O'Malley</name>
      <address>Clinical Trials Unit
Cancer Centre 
St George Hospital
Gray Street
Kogarah NSW 2217</address>
      <phone>+61 2 93501920</phone>
      <fax>+61 2 93503958</fax>
      <email>Linda.O'Malley@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>